You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 12, 2024

CLINICAL TRIALS PROFILE FOR HDM201

✉ Email this page to a colleague

« Back to Dashboard

Clinical Trials for HDM201

Subscribe to access the full database, or Sign Up
Trial ID	Title	Status	Sponsor	Phase	Summary
NCT02143635 ↗	Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt	Completed	Novartis Pharmaceuticals	Phase 1	To determine and evaluate a safe and tolerated dose of HDM201 in adult patients with selected advanced tumors characterized by wild-type TP53.
NCT02295722 ↗	GEMHDM2014 : Gem-HDM HDT and ASCT for Relapsed/ Refractory Lymphoma	Unknown status	Tom Baker Cancer Centre	Phase 1/Phase 2	Objective of study: To evaluate the safety and efficacy of infusional gemcitabine prior to HDM (high-dose melphalan) as HDCT (High Dose Chemotherapy) followed by autologous stem cell transplantation in patients with relapsed/refractory lymphoma.
NCT02295722 ↗	GEMHDM2014 : Gem-HDM HDT and ASCT for Relapsed/ Refractory Lymphoma	Unknown status	AHS Cancer Control Alberta	Phase 1/Phase 2	Objective of study: To evaluate the safety and efficacy of infusional gemcitabine prior to HDM (high-dose melphalan) as HDCT (High Dose Chemotherapy) followed by autologous stem cell transplantation in patients with relapsed/refractory lymphoma.
NCT02343172 ↗	Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma	Completed	Novartis Pharmaceuticals	Phase 1	To determine the MTD/RP2D of the HDM201 and LEE011 combination and evaluate whether the combination is safe and has beneficial effects in patients with liposarcoma.
NCT02601378 ↗	A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma.	Active, not recruiting	Novartis Pharmaceuticals	Phase 1	This study is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumor activity of LXS196 as a single agent and in combination with HDM201 in patients with metastatic uveal melanoma.
NCT02780128 ↗	Next Generation Personalized Neuroblastoma Therapy	Recruiting	Foundation Medicine	Phase 1	The purpose of this research study is to match genomic aberrations in tumor cells at time of relapse to rationally designed combinations of molecularly targeted agents. This study will be done in two parts: Part I: Tumor will be accessed at study entry via a biopsy and subjected to deep sequencing to identify protocol-specified biomarkers for therapy assignment. Part II: If the tumor contains a genetic change defined by the study as being actionable, and other criteria are met, participants will be assigned to therapy based upon the genetic changes identified in the tumor biopsy.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Summary

Clinical Trial Conditions for HDM201

Condition Name

Chart
Table

Condition Name
Intervention	Trials
Colorectal Cancer	2
Acute Myeloid Leukemia	2
Allogeneic Stem Cell Transplantation	1
Malignant Solid Tumor	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH
Intervention	Trials
Leukemia, Myeloid, Acute	4
Leukemia, Myeloid	4
Leukemia	4
Colorectal Neoplasms	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for HDM201

Trials by Country

Map
Table

Trials by Country
Location	Trials
United States	14
Spain	12
Germany	6
France	5
Italy	4
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State
Location	Trials
New York	2
Massachusetts	2
North Carolina	1
Washington	1
Utah	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for HDM201

Clinical Trial Phase

Chart
Table

Clinical Trial Phase
Clinical Trial Phase	Trials
Phase 2	1
Phase 1/Phase 2	6
Phase 1	9
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status
Clinical Trial Phase	Trials
Recruiting	6
Not yet recruiting	4
Active, not recruiting	2
[disabled in preview]	4
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for HDM201

Sponsor Name

Chart
Table

Sponsor Name
Sponsor	Trials
Novartis Pharmaceuticals	11
Centre Leon Berard	3
Novartis	2
[disabled in preview]	3
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type
Sponsor	Trials
Industry	14
Other	8
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.